Filana Therapeutics Inc
FLNA
Company Profile
Business description
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Contact
6801 N. Capital of Texas Highway
Suite 300, Building 1
AustinTX78731
USAT: +1 512 501-2444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
20
Stocks News & Analysis
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
All that glitters is not gold.
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
Shoppers are being hit by double whammy of oil and rising rates.
stocks
ASX data center player sells US assets to bolster balance sheet
Asset sale in response to growing investor concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.20 | 32.10 | 0.35% |
| CAC 40 | 8,299.42 | 237.11 | 2.94% |
| DAX 40 | 24,918.69 | 516.99 | 2.12% |
| Dow JONES (US) | 49,910.59 | 612.34 | 1.24% |
| FTSE 100 | 10,438.66 | 219.55 | 2.15% |
| HKSE | 26,575.10 | 361.32 | 1.38% |
| NASDAQ | 25,838.94 | 512.82 | 2.02% |
| Nikkei 225 | 62,832.29 | 3,319.17 | 5.58% |
| NZX 50 Index | 13,258.28 | 113.09 | 0.86% |
| S&P 500 | 7,365.12 | 105.90 | 1.46% |
| S&P/ASX 200 | 8,875.60 | 30.20 | 0.34% |
| SSE Composite Index | 4,166.84 | 6.67 | 0.16% |